{"id":2888,"date":"2019-10-23T11:00:00","date_gmt":"2019-10-23T11:00:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-perfusion-ab-publ-teckningsoptioner-av-serie-2019-2021-fulltecknat\/"},"modified":"2019-10-23T11:00:00","modified_gmt":"2019-10-23T11:00:00","slug":"xvivo-perfusion-ab-publ-teckningsoptioner-av-serie-2019-2021-fulltecknat","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-teckningsoptioner-av-serie-2019-2021-fulltecknat\/","title":{"rendered":"XVIVO Perfusion AB (publ) teckningsoptioner av serie 2019\/2021 fulltecknat"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong>\u00c5rsst\u00e4mman i XVIXO Perfusion AB (publ) (\u201dXVIVO\u201d) beslutade den 25 april 2019 att emittera h\u00f6gst 351\u00a0000 teckningsoptioner av serie 2019\/2021 till anst\u00e4llda i XVIVO och XVIVO:s svenska dotterbolag med anst\u00e4llningsdatum senast den 18 oktober 2019. Totalt tecknades 351\u00a0000 optioner, vilket inneb\u00e4r att emissionen har fulltecknats.<\/strong><\/div>\n<p><span>Varje teckningsoption ber\u00e4ttigar till teckning av en ny aktie i XVIVO till en teckningskurs motsvarande 150 procent av det volymv\u00e4gda medelv\u00e4rdet av de betalkurser f\u00f6r XVIVO:s aktie som noterats p\u00e5 Nasdaq Stockholm f\u00f6r varje handelsdag under (i)\u00a0 perioden 2 maj 2019 \u2013 15 maj 2019 f\u00f6r personer anst\u00e4llda den 1 maj 2019, och (ii) de 10 f\u00f6reg\u00e5ende handelsdagarna f\u00f6re dag f\u00f6r anst\u00e4llning f\u00f6r de personer som anst\u00e4llts under perioden 2 maj 2019 \u2013 18 oktober 2019. Teckning av aktier med st\u00f6d av teckningsoptionerna kan ske till en kurs av 278,91 kronor under perioden 3 maj 2021 \u2013 31\u00a0maj 2021. <\/span><\/p>\n<p><span>Teckningsoptionerna har emitterats till marknadsv\u00e4rde ber\u00e4knat enligt Black &amp; Scholes optionsv\u00e4rderingsmodell.<\/span><\/p>\n<p><span>Vid fullt utnyttjande av samtliga teckningsoptioner kommer XVIXO:s aktiekapital att \u00f6ka med 8 971,13 kronor, motsvarande en utsp\u00e4dningseffekt om cirka 1,3 procent av det totala antalet aktier och r\u00f6ster i XVIVO.<\/span><\/p>\n<p><span>G\u00f6teborg 23 oktober 2019<br \/><\/span>Magnus Nilsson, VD<br \/>XVIVO Perfusion AB (publ)<\/p>\n<div class=\"mfn-footer\">\n<p><span>F\u00f6r ytterligare information, v\u00e4nligen kontakta: <\/span><\/p>\n<p><span>Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com<br \/>Magnus Nilsson, VD, +46 31-788 21 50, magnus.nilsson@xvivoperfusion.com<\/span><\/p>\n<p><span>F\u00f6r ytterligare information om XVIVO Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, www.xvivoperfusion.com<\/span><\/p>\n<p><span>Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande klockan 13:00 den 23 oktober 2019.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u00c5rsst\u00e4mman i XVIXO Perfusion AB (publ) (\u201dXVIVO\u201d) beslutade den 25 april 2019 att emittera h\u00f6gst 351\u00a0000 teckningsoptioner av serie 2019\/2021&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-2888","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-listing","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>XVIVO Perfusion AB (publ) teckningsoptioner av serie 2019\/2021 fulltecknat - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-teckningsoptioner-av-serie-2019-2021-fulltecknat\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO Perfusion AB (publ) teckningsoptioner av serie 2019\/2021 fulltecknat - XVIVO\" \/>\n<meta property=\"og:description\" content=\"\u00c5rsst\u00e4mman i XVIXO Perfusion AB (publ) (\u201dXVIVO\u201d) beslutade den 25 april 2019 att emittera h\u00f6gst 351\u00a0000 teckningsoptioner av serie 2019\/2021...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-teckningsoptioner-av-serie-2019-2021-fulltecknat\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-teckningsoptioner-av-serie-2019-2021-fulltecknat\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-teckningsoptioner-av-serie-2019-2021-fulltecknat\\\/\",\"name\":\"XVIVO Perfusion AB (publ) teckningsoptioner av serie 2019\\\/2021 fulltecknat - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2019-10-23T11:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-teckningsoptioner-av-serie-2019-2021-fulltecknat\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-teckningsoptioner-av-serie-2019-2021-fulltecknat\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-teckningsoptioner-av-serie-2019-2021-fulltecknat\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO Perfusion AB (publ) teckningsoptioner av serie 2019\\\/2021 fulltecknat\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO Perfusion AB (publ) teckningsoptioner av serie 2019\/2021 fulltecknat - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-teckningsoptioner-av-serie-2019-2021-fulltecknat\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO Perfusion AB (publ) teckningsoptioner av serie 2019\/2021 fulltecknat - XVIVO","og_description":"\u00c5rsst\u00e4mman i XVIXO Perfusion AB (publ) (\u201dXVIVO\u201d) beslutade den 25 april 2019 att emittera h\u00f6gst 351\u00a0000 teckningsoptioner av serie 2019\/2021...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-teckningsoptioner-av-serie-2019-2021-fulltecknat\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-teckningsoptioner-av-serie-2019-2021-fulltecknat\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-teckningsoptioner-av-serie-2019-2021-fulltecknat\/","name":"XVIVO Perfusion AB (publ) teckningsoptioner av serie 2019\/2021 fulltecknat - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2019-10-23T11:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-teckningsoptioner-av-serie-2019-2021-fulltecknat\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-teckningsoptioner-av-serie-2019-2021-fulltecknat\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-teckningsoptioner-av-serie-2019-2021-fulltecknat\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO Perfusion AB (publ) teckningsoptioner av serie 2019\/2021 fulltecknat"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}